Asset Details
Do you wish to reserve the book?
Recent advances in CAR-T cell engineering
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recent advances in CAR-T cell engineering
Do you wish to request the book?
Recent advances in CAR-T cell engineering
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recent advances in CAR-T cell engineering
2020
Overview
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates and resistance were experienced, driving the need to discover engineered CAR-T cells that are more effective for therapeutic use. Innovations in the structure and manufacturing of CAR-T cells have resulted in significant improvements in efficacy and persistence, particularly with the development of fourth-generation CAR-T cells. Paired with an immune modifier, the use of fourth-generation and next-generation CAR-T cells will not be limited because of cytotoxic effects and will be an efficient tool for overcoming the tumor microenvironment. In this review, we summarize the recent transformations in the ectodomain, transmembrane domain, and endodomain of the CAR structure, which, together with innovative manufacturing technology and improved cell sources, improve the prospects for the future development of CAR-T cell therapy.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antigens, Neoplasm - immunology
/ Humans
/ Immunotherapy, Adoptive - methods
/ Immunotherapy, Adoptive - trends
/ Leukemia
/ Lymphoma
/ Lymphoma, Large B-Cell, Diffuse - therapy
/ Medicine
/ Oncology
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy
/ Receptors, Chemokine - immunology
/ Receptors, Chimeric Antigen - agonists
/ Receptors, Chimeric Antigen - genetics
/ Receptors, Chimeric Antigen - immunology
/ Receptors, Chimeric Antigen - metabolism
/ Review
/ T cells
/ T-Cell Antigen Receptor Specificity
/ T-Lymphocytes - transplantation
/ Tumors
